Genomic Vision at the 30th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels from 25 to 26 October 2023

Regulatory News:

Genomic Vision (FR0011799907 – GV, – the “Company”) (Paris:GV), a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of transformed cells is pleased to announce its participation in the 30^th Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Brussels, where GV will present its work in bioproduction and introduce its recently launched HexaCard service.

Since the summer launch of HexaCard, Genomic Vision has witnessed significant interest from industrial players. This new service, designed to revolutionize cell line development, allows the simultaneous analysis of six key parameters, creating a unique identity card for each cell. This comprehensive analysis ensures the selection of the most suitable clones, thereby enhancing productivity and stability while reducing timelines and costs.

The HexaCard service is poised to be a game-changer for the bioproduction industry, as it empowers pharmaceutical and biotech companies to streamline their cell line development processes. By providing a comprehensive characterization of transformed cells in a single assay, HexaCard facilitates quicker and more cost-effective decision-making. It offers a level of precision that was previously unattainable, making it an invaluable asset for those involved in bioproduction and gene and cell therapy.

Genomic Vision's presence at the 30^th Annual ESGCT Congress underscores its commitment to introducing this transformative technology to the European pharmaceutical and biotech markets. The company looks forward to engaging with industry professionals, sharing insights, and building collaborations during the event, and contribute to the advancement of gene therapy, cell therapy, and bioproduction on a global scale. This congress serves as a valuable opportunity for Genomic Vision to engage with peers, foster collaborations, and ultimately drive innovation in the field.

Prakhar Bisht, PhD, Principal Scientist at Genomic Vision, shared his insights on this breakthrough service, saying, "Our presence at the ESGCT congress not only delineates our commitment to support Biomanufacturing and Cell & Gene therapy, but also to introduce our HexaCard platform for services to a wider audience. Our presence at this congress allows us to share our cutting edge solutions with fellow experts and industry leaders."